Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/150971
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Roca Cusachs, Alex | - |
dc.contributor.author | Aracil vilar, Joaquín | - |
dc.contributor.author | Calvo Gómez, Carlos | - |
dc.contributor.author | Vaquer Pérez, José Vicente | - |
dc.contributor.author | Laporta Crespo, Félix | - |
dc.contributor.author | Rojas Serrano, María José | - |
dc.contributor.author | Guglietta, Antonio | - |
dc.contributor.author | Gropper, Savion | - |
dc.contributor.author | Sobrino, Javier | - |
dc.date.accessioned | 2020-02-21T13:46:48Z | - |
dc.date.available | 2020-02-21T13:46:48Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 1755-5914 | - |
dc.identifier.uri | http://hdl.handle.net/2445/150971 | - |
dc.description.abstract | The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double‐blind trial. Patients with newly diagnosed mild‐to‐moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide‐PR (n = 219) or torasemide‐IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide‐PR group (11.6 ± 7.1 mmHg, 95% confidence interval [CI] 10.6-12.5) versus torasemide‐IR (11.3 ± 7.5 mmHg, 95% CI 10.2-12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide‐PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24‐h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide‐PR group (128.4 ± 9.9 mmHg vs. 133.5 ± 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley Hindawi Publishing | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1111/j.1527-3466.2008.00046.x | - |
dc.relation.ispartof | Cardiovascular Therapeutics, 2008, vol. 26, num. 2, p. 91-100 | - |
dc.relation.uri | https://doi.org/10.1111/j.1527-3466.2008.00046.x | - |
dc.rights | cc-by (c) Roca Cusachs, Alex et al., 2008 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Medicaments d'alliberament retardat | - |
dc.subject.classification | Pressió sanguínia | - |
dc.subject.other | Delayed-action drugs | - |
dc.subject.other | Blood pressure | - |
dc.title | Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 602170 | - |
dc.date.updated | 2020-02-21T13:46:48Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
602170.pdf | 281.22 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License